AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27881122 — intervention group
Group type: EXPERIMENTAL
Intervention: WeChat health education intervention (50 malaria prevention and treatment messages)
Number of subjects: 1441
Study 27881122 — intervention group
Group type: COMPARATOR
Intervention: Control group (50 health news messages)
Number of subjects: 1441
Study 27881122 — intervention group
Group type: EXPERIMENTAL
Intervention: WeChat health education intervention
Number of subjects: 1441
Study 24980392 — intervention group
Group type: EXPERIMENTAL
Intervention: DX-2930 (0.1 mg/kg)
Number of subjects: 32
Study 24980392 — intervention group
Group type: EXPERIMENTAL
Intervention: DX-2930 (0.3 mg/kg)
Number of subjects: 32
Study 24980392 — intervention group
Group type: EXPERIMENTAL
Intervention: DX-2930 (1.0 mg/kg)
Number of subjects: 32
Study 24980392 — intervention group
Group type: EXPERIMENTAL
Intervention: DX-2930 (3.0 mg/kg)
Number of subjects: 32
Study 24980392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 22916489 — intervention group
Group type: EXPERIMENTAL
Intervention: Neotype medical drainage bag
Number of subjects: 206
Study 20525230 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice the recommended dietary allowance of 14 micronutrients for 6 months
Number of subjects: 847
Study 20525230 — intervention group
Group type: COMPARATOR
Intervention: Standard recommended dietary allowance of six multivitamins for 6 months
Number of subjects: 847
Study 20525230 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice the recommended dietary allowance of 14 micronutrients in ART stratum
Number of subjects: 847
Study 20525230 — intervention group
Group type: COMPARATOR
Intervention: Standard recommended dietary allowance of six multivitamins in ART stratum
Number of subjects: 847
Study 20525230 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice the recommended dietary allowance of 14 micronutrients in non-ART stratum
Number of subjects: 847
Study 20525230 — intervention group
Group type: COMPARATOR
Intervention: Standard recommended dietary allowance of six multivitamins in non-ART stratum
Number of subjects: 847
Study 20525230 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice the recommended dietary allowance of 14 micronutrients
Number of subjects: 847
Study 20525230 — intervention group
Group type: COMPARATOR
Intervention: Standard recommended dietary allowance of six multivitamins
Number of subjects: 847
Study 18272319 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketalar (ketamine) administered at induction until the end of surgery
Number of subjects: 208
Study 18272319 — intervention group
Group type: COMPARATOR
Intervention: Placebo (physiologic serum) administered in the same condition
Number of subjects: 208
Study 16021001 — intervention group
Group type: EXPERIMENTAL
Intervention: No. 7 lens
Number of subjects: 24
Study 16021001 — intervention group
Group type: COMPARATOR
Intervention: BE lens
Number of subjects: 24
Study 12598279 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure application on the extra 1 point for 10 min
Number of subjects: 25
Study 12598279 — intervention group
Group type: COMPARATOR
Intervention: Pressure application on the control point for 5 min
Number of subjects: 25
Study 9884380 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine for 72 hours
Number of subjects: 9
Study 9884380 — intervention group
Group type: COMPARATOR
Intervention: Control (no dobutamine)
Number of subjects: 9
Study 8613275 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicular phase (days 7 to 10 after menses)
Number of subjects: 33
Study 8613275 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteal phase (days 7 to 10 after the leutenizing hormone surge)
Number of subjects: 33
Study 8613275 — intervention group
Group type: COMPARATOR
Intervention: Stress response
Number of subjects: 33
Study 1830266 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethynylestradiol (30 micrograms) alone
Number of subjects: 10
Study 1830266 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethynylestradiol (30 micrograms) with gestodene (75 micrograms)
Number of subjects: 10
Study 1830266 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethynylestradiol (30 micrograms) with desogestrel (150 micrograms)
Number of subjects: 10
Study 1830266 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of EE2
Number of subjects: 10
Study 6124671 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g methylprednisolone
Number of subjects: 20
Study 6124671 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6124671 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g methylprednisolone (after placebo)
Number of subjects: 20
Study 6124671 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 20
Study 29356438 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco use
Number of subjects: 404
Study 29356438 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol use
Number of subjects: 404
Study 29356438 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis use
Number of subjects: 404
Study 29351770 — intervention group
Group type: EXPERIMENTAL
Intervention: Habitual functional training during short term stays at nursing homes
Number of subjects: 8
Study 25405657 — intervention group
Group type: EXPERIMENTAL
Intervention: Yukon Choice PC
Number of subjects: 2603
Study 25405657 — intervention group
Group type: COMPARATOR
Intervention: XIENCE
Number of subjects: 2603
Study 25405657 — intervention group
Group type: COMPARATOR
Intervention: CYPHER
Number of subjects: 2603
Study 25083133 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program combined with NMES
Number of subjects: 63
Study 25083133 — intervention group
Group type: COMPARATOR
Intervention: Exercise-only program
Number of subjects: 63
Study 21984397 — intervention group
Group type: EXPERIMENTAL
Intervention: On-sight ascent (lead climb or top-rope)
Number of subjects: 19
Study 19786940 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose reteplase (r-PA) plus abciximab
Number of subjects: 38
Study 19786940 — intervention group
Group type: COMPARATOR
Intervention: Full-dose r-PA
Number of subjects: 38
Study 17270340 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 1 mg
Number of subjects: 282
Study 17270340 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 2.5 mg
Number of subjects: 282
Study 17270340 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 5 mg
Number of subjects: 282
Study 17270340 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 10 mg
Number of subjects: 282
Study 17270340 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg
Number of subjects: 282
Study 17270340 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 282
Study 15039508 — intervention group
Group type: EXPERIMENTAL
Intervention: Gut-directed hypnotherapy 1 hour per week for 12 weeks
Number of subjects: 28
Study 15039508 — intervention group
Group type: COMPARATOR
Intervention: Supportive therapy (control group)
Number of subjects: 28
Study 11727074 — intervention group
Group type: EXPERIMENTAL
Intervention: MIST VR (virtual reality simulator)
Number of subjects: 32
Study 11727074 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Z maze-tracking task
Number of subjects: 32
Study 11727074 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic U maze-tracking task
Number of subjects: 32
Study 11727074 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 32
Study 10087431 — intervention group
Group type: EXPERIMENTAL
Intervention: Early introduction of fluindione (20 mg once daily starting on day 1)
Number of subjects: 223
Study 10087431 — intervention group
Group type: COMPARATOR
Intervention: Delayed introduction of fluindione (20 mg once daily starting on day 10)
Number of subjects: 223
Study 7820043 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-chlorodeoxyadenosine (2-CdA)
Number of subjects: 144
Study 7820043 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-chlorodeoxyadenosine (2-CdA) in patients resistant or intolerant to 2'-deoxycoformycin
Number of subjects: 144
Study 7820043 — intervention group
Group type: COMPARATOR
Intervention: pentoxifylline
Number of subjects: 144
Study 3071451 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of aceclofenac
Number of subjects: 0
Study 3071451 — intervention group
Group type: COMPARATOR
Intervention: 650 mg of paracetamol
Number of subjects: 0
Study 29914580 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training group
Number of subjects: 27
Study 29914580 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study 27672397 — intervention group
Group type: EXPERIMENTAL
Intervention: Brazilian propolis toothpaste
Number of subjects: 96
Study 27672397 — intervention group
Group type: COMPARATOR
Intervention: Control group (no propolis toothpaste)
Number of subjects: 96
Study 23652417 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA) followed by vertebroplasty
Number of subjects: 36
Study 23652417 — intervention group
Group type: COMPARATOR
Intervention: Vertebroplasty only
Number of subjects: 36
Study 23735480 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan (TCC)
Number of subjects: 68
Study 23735480 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control (book club)
Number of subjects: 68
Study 23735480 — intervention group
Group type: COMPARATOR
Intervention: Active control (gym exercise)
Number of subjects: 68
Study 21537337 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerine treatment (1.25 mg patch for 6 months)
Number of subjects: 45
Study 21537337 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 45
Study 18359309 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 14527
Study 18359309 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 14527
Study 18359309 — intervention group
Group type: EXPERIMENTAL
Intervention: Both captopril and valsartan
Number of subjects: 14527
Study 18359309 — intervention group
Group type: COMPARATOR
Intervention: Control group (without dm)
Number of subjects: 14527
Study 18359309 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mortality and composite cardiovascular events
Number of subjects: 14527
Study 16894240 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 0
Study 16894240 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0
Study 16894240 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (in mice)
Number of subjects: 0
Study 16894240 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazolidinediones (in vitro treatment of 3T3 F442A adipocytes)
Number of subjects: 0
Study 12953340 — intervention group
Group type: COMPARATOR
Intervention: Double-strength grapefruit juice (DS GFJ) 240 mL tid for 3 days
Number of subjects: 24
Study 12953340 — intervention group
Group type: COMPARATOR
Intervention: Single-strength grapefruit juice (SS GFJ) 240 mL
Number of subjects: 24
Study 12953340 — intervention group
Group type: COMPARATOR
Intervention: Double-strength grapefruit juice (DS GFJ) 240 mL
Number of subjects: 24
Study 12953340 — intervention group
Group type: COMPARATOR
Intervention: Nine glasses of double-strength grapefruit juice (DS GFJ)
Number of subjects: 24
Study 11763944 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Sensitive Maximum Strength dentifrice (5.0% potassium nitrate and 0.454% stannous fluoride)
Number of subjects: 101
Study 11763944 — intervention group
Group type: COMPARATOR
Intervention: Fresh Mint Sensodyne dentifrice (5.0% potassium nitrate and 0.76% sodium monofluorophosphate)
Number of subjects: 101
Study 8646509 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinia melanoma oncolysate (VMO)
Number of subjects: 0
Study 8646509 — intervention group
Group type: COMPARATOR
Intervention: Placebo of live vaccinia vaccine virus (V)
Number of subjects: 0
Study 1513726 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized albuterol (0.15 mg/kg)
Number of subjects: 25
Study 1513726 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 25
Study 6475060 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately high-dose methotrexate (MTX) 250 mg/m2 to 750 mg/m2 at 10-day intervals
Number of subjects: 40
Study 6475060 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methotrexate (MTX) 5 to 15 g at 10-day intervals
Number of subjects: 40
Study 6475060 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-high therapy with a cumulative dose of 205 g MTX
Number of subjects: 40
Study 6475060 — intervention group
Group type: EXPERIMENTAL
Intervention: Two cases of severe malignant non-Hodgkin's lymphoma treated with MTX (1 patient received 2 X 1 g MTX, the other received a single dose of 5 g MTX)
Number of subjects: 40
Study 6475060 — intervention group
Group type: EXPERIMENTAL
Intervention: Complications from high-dose MTX therapy
Number of subjects: 40
Study 6475060 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose MTX therapy
Number of subjects: 40
Study 31436446 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational strategies
Number of subjects: 352
Study 31436446 — intervention group
Group type: COMPARATOR
Intervention: Empathic reflections
Number of subjects: 352
Study 31436446 — intervention group
Group type: COMPARATOR
Intervention: Spoken voice
Number of subjects: 352
Study 31436446 — intervention group
Group type: COMPARATOR
Intervention: Animated narrator
Number of subjects: 352
Study 29287863 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal ketamine (1.5 mg/kg)
Number of subjects: 63
Study 29287863 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl (1.5 mcg/kg)
Number of subjects: 63
Study 29287863 — intervention group
Group type: COMPARATOR
Intervention: Intravenous paracetamol (10 mg/kg)
Number of subjects: 63
Study 27482002 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose omega-3 fatty acids
Number of subjects: 358
Study 27482002 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 358
Study 24612095 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone intravitreal implant
Number of subjects: 60
Study 24612095 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab injections
Number of subjects: 60
Study 23019837 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Midazolam (0.5 mg/kg)
Number of subjects: 40
Study 23019837 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Diazepam (0.5 mg/kg)
Number of subjects: 40
Study 23019837 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Midazolam (0.06 mg/kg)
Number of subjects: 40
Study 23019837 — intervention group
Group type: COMPARATOR
Intervention: Oral Placebo
Number of subjects: 40
Study 19734131 — intervention group
Group type: EXPERIMENTAL
Intervention: Spa therapy plus home exercises and usual medical treatment
Number of subjects: 382
Study 19734131 — intervention group
Group type: COMPARATOR
Intervention: Exercises and usual treatment (Control)
Number of subjects: 382
Study 19734131 — intervention group
Group type: COMPARATOR
Intervention: Quality of life (Short Form 36)
Number of subjects: 382
Study 19734131 — intervention group
Group type: COMPARATOR
Intervention: Patient acceptable symptom state
Number of subjects: 382
Study 17914134 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 0
Study 17914134 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium lactate (daily dose about 800 mg calcium)
Number of subjects: 0
Study 17914134 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium phosphate (daily dose about 800 mg calcium)
Number of subjects: 0
Study 17914134 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat milk (daily dose about 800 mg calcium)
Number of subjects: 0
Study 15770505 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous anesthesia (TIVA)
Number of subjects: 52
Study 15770505 — intervention group
Group type: COMPARATOR
Intervention: Balanced anesthesia (BA)
Number of subjects: 52
Study 12475451 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular cooling during primary PCI
Number of subjects: 42
Study 12475451 — intervention group
Group type: COMPARATOR
Intervention: Control group (no endovascular cooling)
Number of subjects: 42
Study 9802138 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumour specimens
Number of subjects: 35
Study 9802138 — intervention group
Group type: COMPARATOR
Intervention: Non-tumour specimens
Number of subjects: 35
Study 9802138 — intervention group
Group type: COMPARATOR
Intervention: Non-tumour mucosa
Number of subjects: 35
Study 7625364 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet (30% fat, 10% saturated)
Number of subjects: 63
Study 7625364 — intervention group
Group type: COMPARATOR
Intervention: Baseline diet (37% fat, 15% saturated)
Number of subjects: 63
Study 2506337 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.694 g of alcohol per kg b.wt.)
Number of subjects: 24
Study 2506337 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 24
Study 362900 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral gentamicin sulfate therapy (2.5 mg/kg every six hours for one week)
Number of subjects: 42
Study 362900 — intervention group
Group type: COMPARATOR
Intervention: Dextrose-and-water placebo
Number of subjects: 42
Study 29894642 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-fat chocolate milk (CM)
Number of subjects: 0
Study 29894642 — intervention group
Group type: COMPARATOR
Intervention: Sports beverage (SB)
Number of subjects: 0
Study 27798224 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphetamine (10 mg)
Number of subjects: 2
Study 27798224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 26101142 — intervention group
Group type: EXPERIMENTAL
Intervention: Virgin Argan oil (VAO)
Number of subjects: 37
Study 26101142 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 37
Study 23945724 — intervention group
Group type: EXPERIMENTAL
Intervention: New guidelines group (NGG) with counseling to continue breastfeeding, offer red meat ≥3 d/wk, and offer fruit and vegetables daily
Number of subjects: 85
Study 23945724 — intervention group
Group type: EXPERIMENTAL
Intervention: New guidelines group (NGG)
Number of subjects: 85
Study 23945724 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 85
Study 23945724 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 85
Study 19948948 — intervention group
Group type: EXPERIMENTAL
Intervention: Trospium 60 mg extended-release once daily
Number of subjects: 24
Study 19948948 — intervention group
Group type: COMPARATOR
Intervention: Trospium 20 mg immediate-release tablets twice daily
Number of subjects: 24
Study 20071813 — intervention group
Group type: COMPARATOR
Intervention: 4 mg Ondansetron (Group O)
Number of subjects: 150
Study 20071813 — intervention group
Group type: COMPARATOR
Intervention: 8 mg Dexamethasone (Group D)
Number of subjects: 150
Study 20071813 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg Ondansetron plus 8 mg Dexamethasone (Group OD)
Number of subjects: 150
Study 17064231 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visiting intervention for asthma self-management
Number of subjects: 0
Study 14637327 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated olfactory presentations of a cheeseburger followed by apple pie as the new food stimulus.
Number of subjects: 0
Study 14637327 — intervention group
Group type: EXPERIMENTAL
Intervention: Food reinforcement task with cheeseburger followed by apple pie.
Number of subjects: 0
Study 11087063 — intervention group
Group type: EXPERIMENTAL
Intervention: Snoezelen (sensory environment)
Number of subjects: 73
Study 11087063 — intervention group
Group type: COMPARATOR
Intervention: Traditional relaxation programme
Number of subjects: 73
Study 8831653 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation technique
Number of subjects: 60
Study 8831653 — intervention group
Group type: COMPARATOR
Intervention: Reading group (control)
Number of subjects: 60
Study 1346008 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis
Number of subjects: 248
Study 1346008 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis (Control)
Number of subjects: 248
Study 6548392 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial oral elixir of theophylline
Number of subjects: 6
Study 6548392 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal suppository of aminophylline
Number of subjects: 6
Study 6548392 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal enema of theophylline monoethanolamine
Number of subjects: 6
Study 30176671 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg WP-0508ST
Number of subjects: 95
Study 30176671 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg WP-0508ST
Number of subjects: 95
Study 30176671 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 95
Study 29381502 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac educational program
Number of subjects: 127
Study 27482610 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 3.0 mg
Number of subjects: 5131
Study 27482610 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5131
Study 24939916 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation intervention (n = 104) incorporating psychosocial and pharmacological support for 4 months postdischarge
Number of subjects: 205
Study 24939916 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual control (n = 101)
Number of subjects: 205
Study 24939916 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation intervention (n = 104)
Number of subjects: 205
Study 23131890 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride 400 mg
Number of subjects: 0
Study 23131890 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 0
Study 23131890 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 0
Study 23131890 — intervention group
Group type: COMPARATOR
Intervention: Aripiprazole
Number of subjects: 0
Study 23131890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20729233 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-monthly 3-week treatments with oral ciprofloxacin and inhaled colistin
Number of subjects: 65
Study 20729233 — intervention group
Group type: COMPARATOR
Intervention: Placebo controls
Number of subjects: 65